A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Desh Deepak | - |
dc.contributor.author | Han, Ihn | - |
dc.contributor.author | Choi, Eun-Ha | - |
dc.contributor.author | Yadav, Dharmendra Kumar | - |
dc.date.accessioned | 2024-07-08T05:00:33Z | - |
dc.date.available | 2024-07-08T05:00:33Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1467-3037 | - |
dc.identifier.issn | 1467-3045 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91814 | - |
dc.description.abstract | SARS-CoV-2 (severe acute respiratory syndrome) is highly infectious and causes severe acute respiratory distress syndrome (SARD), immune suppression, and multi-organ failure. For SARS-CoV-2, only supportive treatment options are available, such as oxygen supportive therapy, ventilator support, antibiotics for secondary infections, mineral and fluid treatment, and a significant subset of repurposed effective drugs. Viral targeted inhibitors are the most suitable molecules, such as ACE2 (angiotensin-converting enzyme-2) and RBD (receptor-binding domain) protein-based inhibitors, inhibitors of host proteases, inhibitors of viral proteases 3CLpro (3C-like proteinase) and PLpro (papain-like protease), inhibitors of replicative enzymes, inhibitors of viral attachment of SARS-CoV-2 to the ACE2 receptor and TMPRSS2 (transmembrane serine proteinase 2), inhibitors of HR1 (Heptad Repeat 1)-HR2 (Heptad Repeat 2) interaction at the S2 protein of the coronavirus, etc. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein's ability to fuse to the membrane. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein's ability to fuse to the membrane. Even with the tremendous progress made, creating effective drugs remains difficult. To develop COVID-19 treatment alternatives, clinical studies are examining a variety of therapy categories, including antibodies, antivirals, cell-based therapy, repurposed diagnostic medicines, and more. In this article, we discuss recent clinical updates on SARS-CoV-2 infection, clinical characteristics, diagnosis, immunopathology, the new emergence of variant, SARS-CoV-2, various approaches to drug development and treatment options. The development of therapies has been complicated by the global occurrence of many SARS-CoV-2 mutations. Discussion of this manuscript will provide new insight into drug pathophysiology and drug development. | - |
dc.format.extent | 34 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors | - |
dc.type | Article | - |
dc.identifier.wosid | 000914966800001 | - |
dc.identifier.doi | 10.3390/cimb45010028 | - |
dc.identifier.bibliographicCitation | CURRENT ISSUES IN MOLECULAR BIOLOGY, v.45, no.1, pp 400 - 433 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85146799961 | - |
dc.citation.endPage | 433 | - |
dc.citation.startPage | 400 | - |
dc.citation.title | CURRENT ISSUES IN MOLECULAR BIOLOGY | - |
dc.citation.volume | 45 | - |
dc.citation.number | 1 | - |
dc.type.docType | Review | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | variant | - |
dc.subject.keywordAuthor | antibody | - |
dc.subject.keywordAuthor | treatment | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | neutralization therapy | - |
dc.subject.keywordAuthor | drug treatment | - |
dc.subject.keywordPlus | COVID-19 PATIENTS | - |
dc.subject.keywordPlus | SINGLE-CENTER | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | IVERMECTIN | - |
dc.subject.keywordPlus | REMDESIVIR | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | SARS | - |
dc.subject.keywordPlus | MERS | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.